Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06054425 · ClinicalTrials.gov registry record · Phase 1
A Study to Compare the Bioavailability of Intravenously Infused Risankizumab Manufactured by Two Different Processes in Healthy Adults
A Phase 1 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT06054425 is a Phase 1 study that has completed, run by AbbVie. The registered enrollment target is 48 participants.
The verdict
NCT06054425, a Phase 1 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
The objective of this study is to assess the bioavailability of risankizumab liquid vial manufactured with the new process (CMC3) relative to the current process (CMC2).
Interventions
- DRUG Risankizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2023-11-20 |
| Est. Completion | 2024-05-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06054425
The ClinicalTrials.gov registry entry for NCT06054425 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Risankizumab is the first listed.
NCT06054425 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06054425 about?
NCT06054425 is a clinical study titled "A Study to Compare the Bioavailability of Intravenously Infused Risankizumab Manufactured by Two Different Processes in Healthy Adults". The objective of this study is to assess the bioavailability of risankizumab liquid vial manufactured with the new process (CMC3) relative to the current process (CMC2).
What is the current status of trial NCT06054425?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2023-11-20. Estimated completion is 2024-05-06.
What interventions are being tested in trial NCT06054425?
The interventions under investigation include: Risankizumab (DRUG).
Who is sponsoring clinical trial NCT06054425?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.